OR-AIRSHIP
27.10.2021 15:02:16 CEST | Business Wire | Press release
Later today at Elevate 2021 , the mobile app experience company Airship will debut its next-generation App Experience Platform that makes it simple to create, measure and perfect in-app experiences crucial to onboarding app audiences, building user understanding for next-level personalization, and advancing monetization goals through a data-led approach. New innovations including Airship Tours, Airship Surveys and Airship Preference Center, give business users full control to easily create, automate and adapt rich, native app experiences for continuous onboarding and first-party and zero-party data collection without ongoing developer support or having to update apps in the App Store or Google Play.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005301/en/
“Mobile apps have become the preferred destination for customers due to simple, contextual interactions, faster transactions and streamlined experiences that elegantly span their digital and physical worlds, like click-and-collect, loyalty and subscription programs, and direct-to-consumer commerce to name a few,” said Brett Caine, CEO and president, Airship. “However, realizing the full business potential of apps is challenging with progress hampered by reliance on development resources and cyclical app updates that have left marketers, and the industry-at-large, approaching apps as another promotional channel rather than creating reciprocal value exchanges necessary for sustained relationships.”
Mobile app retention rates average only 28 percent after day one and 15 percent after the first week1 , yet app users produce 3.5X more revenue than other shoppers and they are 3X more likely to make a repeat purchase2 . First impressions are critical, and Airship Tours allows marketers and mobile product owners to easily create, edit and manage full-screen, interactive walkthroughs (up to 10 screens long) that showcase the value of the app and how to get started. Tours can drive onboarding, feature adoption, loyalty enrollment or any number of key milestone activities such as completing their profile, authenticating within the app, opting into notifications, setting preferences and more. Tours can be triggered based on customers’ real-time behaviors and attributes, enabling exceptionally relevant and personalized treatments, and real-time analytics that highlight ways to improve the experience and outcomes.
Airship Surveys allow marketers and mobile product owners to collect granular feedback from users while they are engaged with the app, gaining actionable insights to improve app experiences without developer involvement. Surveys can be targeted to customers based on their attributes and real-time behaviors, such as purchases, engagement with a new feature, abandoned carts or Tours completed, and resulting data can be analyzed by customer segments for more nuanced understanding and to target future campaigns. Pre-built survey templates for NPS and product feedback make it easy to get started.
Announced last month, Airship Preference Center now encompasses all re-engagement messaging channels (e.g., SMS and email), enabling customers to control the types of content they receive on different channels in one place. Marketers and mobile product owners can also take advantage of opt-in forms for SMS and email to place on their websites, and can see all channels a user has opted in to from lookups within the Airship App Experience Platform.
Availability
These new solutions will be available over the coming months. Brands interested in getting first access can request to join Airship’s special access program .
Airship is a Leader in “The Forrester Wave™: Mobile Engagement Automation, Q3 2020 ,” receiving the highest score in the Strategy category and the second highest score in the Current Offering category.
About Airship
No one knows more, does more, or cares more when it comes to helping brands master mobile app experiences than Airship. From the beginning of apps, we powered the first commercial messages and then expanded our data-led approach to all re-engagement channels (mobile wallet, SMS, email), app UX experimentation, proactive in-app conversations and now rich in-app experiences that business users can create and adapt on their own — with no ongoing developer support or app update required.
From the trillions of mobile app interactions we’ve powered for thousands of global brands, we’ve been there, and done that, lending our solutions and expertise to help apps become the pinnacle of elegant customer experiences and winning brand loyalty strategies. One could say Airship has one mission: to go where mobile will take your business.
For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .
1
Adjust "Mobile App Trends 2021: A Global Benchmark of App Performance"
2
eMarketer, “Frictionless Commerce,” May 21, 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005301/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom